
1. j immunol. 2004 feb 1;172(3):1763-7.

selective killing vaccinia virus ll-37: implications eczema vaccinatum.

howell md(1), jones jf, kisich ko, streib je, gallo rl, leung dy.

author information: 
(1)division allergy immunology, department pediatrics, national jewish 
medical research center, denver, co 80206, usa.

possible bioterrorism smallpox led resumption smallpox
(vaccinia virus) immunization. one complication, eczema vaccinatum, occurs
primarily patients atopic dermatitis (ad). skin lesions patients 
ad, psoriasis, deficient cathelicidin antimicrobial peptide
(ll-37) human beta-defensin-2 (hbd-2). hypothesized defect may
explain susceptibility patients ad eczema vaccinatum. wyeth
vaccine strain vaccinia virus incubated varying concentrations of
human (ll-37) murine (cramp) cathelicidins, human alpha-defensin (hbd-1,
hbd-2), control peptide. outcomes included quantification viral pfu,
vaccinia viral gene expression quantitative real-time rt-pcr, changes in
virion structure transmission electron microscopy. cramp knockout mice and
control animals inoculated skin pricks 2 x 10(5) pfu vaccinia and
examined daily pox development. physiologic amounts human murine
cathelicidins (10-50 micro m), human defensins, antibacterial
activity, resulted vitro reduction vaccinia viral plaque formation
(p < 0.0001), vaccinia mrna expression (p < 0.001), alteration vaccinia
virion structure. vivo vaccinia pox formation occurred four six cramp
knockout animals one 15 control mice (p < 0.01). data
support role cathelicidins inhibition orthopox virus (vaccinia)
replication vitro vivo. susceptibility patients ad to
eczema vaccinatum may due deficiency cathelicidin.

doi: 10.4049/jimmunol.172.3.1763 
pmid: 14734759  [indexed medline]

